Prakt. lékáren. 2011; 7(6): 256-257
Febuxostat
- Oddělení klinické farmakologie FN Plzeň
Febuxostat is a new non – purine selective xanthioxidase inhibitors that is more potent than allopurinol. Its efficacy was confirmed in
phase III trials, where significantly more febuxostat treated patients met the primary endpoint (serum urate < 360 μmol/l), febuxostat was
more effective in subset of patients with impaired renal function. Long term extension studies confirmed the efficacy and tolerability
of febuxostat. In patiens with target uric acid level, the incidence of gout flares fell continually and tophi resolved in more than 50 % of
patiens. The incidence of averse events during febuxostat treatment is probably similar to allopurinol. Febuxostat is new, effective drug,
which offers a new option for the long term treatment of gout.
Keywords: hyperuriacemia, gout, febuxostat
Published: December 1, 2011 Show citation
References
- Pavelka K. Nové pohledy na léčbu hyperurikemie a dny. Interní Med 2008; 10(6): 268-272.
- Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout. Part II: Manegement. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65: 1312-1324.
Go to original source... 
Go to PubMed... - Lawrence Edwards N. Febuxostat: a new treatment for hyperuricaemia in gout. Rheumatology (Oxford) 2009; 48: 15-19. Go to original source...
- Uloric full prescribing information. www.accessdata.fda. gov/drugsatfda_docs/label/2011/021856s003lbl.pdf.
- Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum 2005; 52: 916-923. Go to original source... Go to PubMed...
- Becker MA, Schumacher HR Jr, Wortmann RL. Febuxostat compared with allopurinol in patiens with hyperuricaemia and gout. N Engl J Med 2005; 353(23): 2450-2461. Go to original source... Go to PubMed...
- Schumacher HR Jr, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008; 59: 1540-1548. Go to original source... Go to PubMed...
- Becker M, MacDonald P, Hunt B, et al. Urate-lowering (UL) efficacy and safety of daily treatment of gouty subjects with febuxostat (FEB) of allopurinol (ALLO): FACT and APEX randomized controlled trials (RCTS). Ann Rheum Dis 2010; 69(Suppl. 3): 122.
- Wortmann RL, Becker MA, Schumacher HR. Effect of febuxostat or allopurinol on the clinical manifestations of gout: reduction in gout flares and tophus size over time in the EXCEL trial. Abstract presented at the American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Scientific Meeting; 10-15 November 2006; Washington, DC, USA. [Abstract No. 1592].
- Schumacher HR Jr, Becker MA, Lloyd E, MacDonald PA, Lademacher C. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford). 2009; 48: 188-194. Go to original source... Go to PubMed...
- Becker MA, Schumacher HR, Espinoza LR, et al. The urate - lowering efficacy and safety of febuxostat in the treatment of hyperuricemia of gout: the CONFIRMS trial. Arthritis Research Therapy 2010; 12: R63. Go to original source... Go to PubMed...